The Efficacy of Curcumin Patch as an Adjuvant Therapeutic Agent in Managing Acute Orofacial Pain on the Post-Cleft Lip and Cleft Palate Surgery Patients: A Pragmatic Trial

Tantry Maulina1 Yohanes Yoppy Purnomo1 Salshabia Gabrielle Raissa Tasman2
Endang Sjamsudin1 Amaliya Amaliya3

1 Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, University of Padjadjaran, Bandung, Indonesia
2 Oral and Maxillofacial Surgery Department, Faculty of Dentistry, University of Padjadjaran, Bandung, Indonesia
3 Department of Periodontology, Faculty of Dentistry, University of Padjadjaran, Bandung, Indonesia

Address for correspondence Tantry Maulina, MH, PhD, Department of Oral Surgery and Maxillofacial Surgery, Faculty of Dentistry, University of Padjadjaran, Jl. Sekeloa Selatan no. 1, Bandung 40132, Indonesia (e-mail: tantry.maulina@fkg.unpad.ac.id; tantry.maulina@ru.nl).

Abstract

Objective Acute pain is one of the most common pains experienced by post-cleft lip or cleft surgery patients regardless of the administration of analgesic agents. This current study aimed to evaluate the efficacy of a curcumin patch as an adjuvant analgesic agent on the post-cleft lip and cleft palate surgery patients.

Materials and Methods Fifty-five (33 male; 22 female) participants aged 36 months or less are recruited in this pragmatic trial and randomly assigned to a control group, where no curcumin patch was applied; or the experimental group, where the participants wore a curcumin patch with a dosage of 100 mg. All participants (regardless of the group) received a standardized postsurgery analgesic agent immediately after the surgery was completed. A face, leg, activity, cry, and consolability (FLACC) scale was used to evaluate pain levels for three subsequent time points.

Statistical Analysis All data were then analyzed by using the Mann–Whitney U test to compare the mean differences between the two groups.

Results The results of the current study revealed that there was no significant difference found between the control and the experimental group when mean pain scores were compared for the first evaluation time. Yet, there was a significant difference ($p < 0.01$) between the two groups’ mean pain scores on the second evaluation time.

Conclusion Curcumin patch was found to be effective when used as an adjuvant analgesic agent to reduce acute-orofacial postsurgery pain in cleft lip and cleft surgery patients.

Keywords ► curcumin patch ► orofacial pain ► cleft lip surgery ► acute pain ► postoperative pain ► activity ► cry ► consolability ► cleft palate surgery


This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
Introduction

The latest meta-analysis study performed by Salari et al about the prevalence of cleft lip, cleft palate, as well as cleft lip and palate, revealed that the prevalence of cleft palate based on the 59 studies included in the meta-analysis was 0.33 in every 1,000 live birth (95% confidence interval [CI]: 0.28–0.38); the prevalence of cleft lip based on the 57 studies included was 0.3 in every 1,000 live birth (95% CI: 0.26–0.34); and the prevalence of cleft lip and palate based on 55 studies included was 0.45 in every 1,000 live birth (95% CI: 0.38–0.52), indicating the high prevalence of these birth defects and their common occurrence in human beings. Aside from its high prevalence, patients and/or family member of patients with cleft lip and/or cleft palate also reported impacted quality of life.

Considering the high prevalence as well as the impact on patients’ quality of life, the treatment of cleft lip and/or cleft palate is performed early in life. The course of treatment for cleft lip and/or cleft palate patients consists of several stages, with surgery being the first corrective procedure to go through. It is important to conduct surgery as early as possible as it is crucial to make the patient has a (close to) normal anatomical structure that can function as (near to) normal as possible. Unfortunately, similar to any other invasive approach, surgery has postoperative consequences, one of which is postoperative pain, regardless of the existing postoperative pain management. In a study conducted by Augsornwan et al, it was reported that 48% of patients who underwent palatoplasty have moderate-to-severe postoperative pain at the 4th hour, indicating the importance of adequate pain management, considering that patients of labioplasty (corrective surgery of cleft lip) and palatoplasty (corrective surgery of cleft palate) are mainly very young children that cannot properly communicate their pain level (yet).

Unlike postoperative pain control in adult patients that can involve the usage of opioid analgesics, the usage of opioid analgesics in infants who underwent surgery has been reported for its disadvantages, namely postoperative sedation, respiratory depression, as well as consequent airway compromise. Therefore, various combinations of methods have been applied to reduce this postoperative pain experienced by postlabioplasty and postpalatoplasty patients, namely the addition of local anesthesia procedure to the standardized anesthesia procedure, the usage of opioids and the usage of nonsteroid anti-inflammatory drugs. Yet, regardless of these various attempts, no single postoperative pain control procedure for postlabioplasty and postpalatoplasty has been strongly recommended, which might be due to the various results.

Considering that most of the current postoperative pain control methods consist of invasive procedure(s) with possible additional side effects, ongoing research that evaluates the efficacy of postoperative pain control methods for postlabioplasty and postpalatoplasty patients is currently taking place, including the ones that involve the utilization of natural ingredients. One of the natural ingredients that have been widely evaluated and acknowledged for its analgesic effect is curcumin. Based on these previous findings, a study that aimed at evaluating the analgesic effect of curcumin was designed. Therefore, the current study aimed to evaluate the effectiveness of a curcumin patch as an adjuvant analgesic agent in managing acute postoperative pain in postlabioplasty and/or postpalatoplasty patients. Considering that the patient will have a postoperative wound in the oral and facial area, the curcumin patch will be placed on the patient’s chest.

Materials and Methods

Fifty-five (33 male; 22 female) participants aged 36 months old or younger that went through corrective surgery for a cleft lip or cleft palate at Unpad Dental Hospital in Bandung, Indonesia, were recruited for the current study. Prior to the start of the study, ethical clearance was gained from the Universitas Padjadjaran Research Ethics Committee (No. 715/UN6.KEP/EC/2020). To confirm, every procedure and ethical aspect of the current research has been conducted in full accordance with the World Medical Association Declaration of Helsinki. All participants signed informed consent to consent to their participation and any future scientific publication as the result of their participation in the current study.

Inclusion and Exclusion Criteria

Participants that fulfilled the following inclusion criteria (1) had completed the cleft lip and/or cleft palate surgery procedure; (2) aged 36 months or less; (3) had no allergic history to curcumin; (4) had an initial pain score of 3 or greater than 3 on a scale of 0–10; (5) did not have any injuries at other parts of the body that may have the potential to cause pain, aside from the postoperative wounds, were recruited. Those who (1) consumed additional pain or anti-inflammatory medication in addition to the curcumin patch or the standard analgesic medication prescribed by the doctor in charge and (2) removed the curcumin patch position from the initial location given by the investigator during the study period were excluded from the study.

Sample Size Calculation

The sampling in this study was performed by using a non-probability sampling technique with a purposive sampling type. The sample size calculation is performed using the following formula:

\[
n_1 = n_2 = \left[ \frac{(\alpha + Z^2 \beta^2)/2}{X \bar{X}^2} \right]^{1/2}
\]

\[
n_1 = n_2 = \left[ \frac{(1.64 + 0.84)^2}{20 - 10} \right]^{1/2}
\]

\[n = 24.60 \approx 25\ sample\]

Information

\[n_1 = n_2 = \text{sample size}\]

\[Z\alpha = \text{type I error} = 5\% (Z\alpha \text{ value based on } Z \text{ table is } 1.64)\]
\[ Z_\beta = 20\% \text{, type II error, (the } Z_\beta \text{ value based on the Z table is 0.84)} \]

\[ X_1 - X_2 = \text{minimum difference which is considered significant.} \]

\[ S = \text{Because there is no data regarding the standard deviation of the mean difference between patients receiving curcumin and those receiving standard drugs, the researchers suspect that the standard deviation is twice the minimum of the mean difference that is considered significant } = 2 \times 10 = 20. \]

Based on the above calculations, the number of participants for each group is 25 participants.

**Curcumin Patch**

The curcumin patch was formulated from a mixture of curcumin extract (obtained from an Indonesian national brand Sidomuncul), hydroxypropyl methylcellulose, ethyl cellulose, polyvinylpyrrolidone, Nipagin, Nipasol, Tween 80, and 95% ethanol. The curcumin patch was in a form of a 6 cm × 10 cm patch (Fig. 1). Every patch contained 100 mg of curcumin and was prepared based on the procedure described in the previous study. Once the anesthesia effect wore off, our field investigator applied the curcumin patch to the chest area of the participant (Fig. 2). The patch was applied for 8 hours before it was removed.

**Study Design**

All participants in this study followed the postsurgery standardized operational procedures (SOP) for cleft lip or cleft lip surgery patients. According to the SOP, once the surgical procedure was completed, participants who weighed more than 10 kg received 100 mg suppository ketoprofen, while participants who weighed less than 10 kg received 50 mg. The next dose of ketoprofen was registered 12 hours after the first dose.

**Randomization and Blinding**

Once the participants completed the operation and received the standard postsurgery analgesic agent, initial pain evaluation by the #1 and #2 field researchers was performed. Participants were then randomly assigned to the control group, where the participants did not receive a curcumin patch; or the treatment group, in which the participants received a 100 mg curcumin patch. The #3 field researcher that was assigned for curcumin placement took a sealed envelope that contained the name of the group the participant was assigned to. Once revealed, this #3 field researcher made a note about which group the patient was assigned to and performed the patch placement procedure. Therefore, the field researchers who were assigned to perform the pain evaluation did not have the knowledge of which group the participant was assigned to.

**Pain Evaluation**

The pain evaluation was performed by two field researchers simultaneously by using the face, leg, activity, cry, and consolability (FLACC) pain scale. The FLACC is a scale that consists of five subsections that are used to assess pain in children aged from 2-month-old to 7-year-old who are unable to communicate their pain. It has been validated and tested for reliability and validity in several previous studies. For each subsection, the pain level is scored as 0, 1, or 2. Therefore, the lowest total scoring would be 0 (zero), while the highest is 10 (ten). Further explanation of the FLACC and the scoring system can be viewed in previous studies.\(^{19,20}\)

**Data Analysis**

Prior to the main analysis, all data were analyzed by the Kolmogorov–Smirnov normality test. The data were then
analyzed by the Mann–Whitney U test to compare the mean differences between the two groups.

**Results**

This current study recruited 55 participants aged between 0 and 36 months old, where most of the participants are males aged between 0 and 18 months (Table 1). Most of the participants went through a labioplasty procedure. Three participants went through a labiopalatoplasty procedure, which means the participants underwent two procedures (labioplasty combined with palatoplasty) at once. Out of these three participants, two participants were in the experimental group, and one participant was in the control group.

Pain evaluation by using FLACC revealed that the mean pain score immediately after the general anesthesia wore off (T0) for both groups from a scale of 0 to 10 was 8.02 (standard deviation [SD] = 1.99), while the pain score in the control group was 7.54 (SD = 2.12) and the experimental group was 8.52 (SD = 1.76) (Table 2). The application of the curcumin patch in the experimental group resulted in significant pain score reduction, which resulted in a mean pain score of 2.48 for the 8th hour postoperative pain evaluation (T2). Although the control group also showed pain reduction, the T2 pain score for the control group was still higher than those of the experimental group.

For the main analysis, a Mann–Whitney U test that was used to evaluate the pain score difference between the control group and the experimental group showed no significant differences between the first evaluation point (T0) and the second evaluation point (T1 = four hours after the first evaluation point). While for the third evaluation point (T2= eight hours after the first evaluation point), there was a significant difference (p = 0.005) for the mean pain score (Table 3). As for side effects, no side effects of the curcumin patch in the current study were reported nor detected.

**Discussion**

The current study revealed that most of the participants were male participants. This finding is consistent with previous findings, of which the male predominance in these types of birth defects was mainly reported. In a literature review by Mairaj et al, it was revealed that male

---

**Table 1** Demographical and clinical characteristics of the participants

<table>
<thead>
<tr>
<th>Variable</th>
<th>Number of participants (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sex</strong></td>
<td>Female</td>
</tr>
<tr>
<td>Male</td>
<td>33 participants</td>
</tr>
<tr>
<td>Female</td>
<td>22 participants</td>
</tr>
<tr>
<td><strong>Age</strong></td>
<td></td>
</tr>
<tr>
<td>0–18 months</td>
<td>36 participants</td>
</tr>
<tr>
<td>19–36 months</td>
<td>19 participants</td>
</tr>
<tr>
<td><strong>Type of operation</strong></td>
<td></td>
</tr>
<tr>
<td>Labioplasty</td>
<td>33 participants</td>
</tr>
<tr>
<td>Palatoplasty</td>
<td>19 participants</td>
</tr>
<tr>
<td>Labiopalatoplasty</td>
<td>3 participants</td>
</tr>
<tr>
<td><strong>Group</strong></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>28 participants</td>
</tr>
<tr>
<td>Treatment</td>
<td>27 participants</td>
</tr>
</tbody>
</table>

**Table 2** Comparison of the pain score between the control group and the treatment group by using FLACC pain scale

<table>
<thead>
<tr>
<th>Group</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Both</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0 (immediately after anesthesia wore off)</td>
<td>3</td>
<td>10</td>
<td>8.02</td>
<td>1.995</td>
</tr>
<tr>
<td>T1 (4 hours after the first evaluation)</td>
<td>0</td>
<td>8</td>
<td>3.96</td>
<td>2.045</td>
</tr>
<tr>
<td>T2 (8 hours after the first evaluation)</td>
<td>0</td>
<td>9</td>
<td>3.05</td>
<td>1.890</td>
</tr>
<tr>
<td><strong>Control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>3</td>
<td>10</td>
<td>7.54</td>
<td>2.117</td>
</tr>
<tr>
<td>T1</td>
<td>1</td>
<td>8</td>
<td>4.04</td>
<td>1.953</td>
</tr>
<tr>
<td>T2</td>
<td>1</td>
<td>8</td>
<td>3.61</td>
<td>1.685</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T0</td>
<td>4</td>
<td>10</td>
<td>8.52</td>
<td>1.762</td>
</tr>
<tr>
<td>T1</td>
<td>0</td>
<td>8</td>
<td>3.89</td>
<td>2.172</td>
</tr>
<tr>
<td>T2</td>
<td>0</td>
<td>9</td>
<td>2.48</td>
<td>1.949</td>
</tr>
</tbody>
</table>

Abbreviations: FLACC, face, leg, activity, cry, and consolability; SD, standard deviation.
predominance was reported for the prevalence of cleft lip and palate with a male/female sex ratio of 1.81 (CI 95%: 1.75–1.86). In another study conducted by Martelli et al, it was reported that there was a strong association found between the male gender and the presence of clefts (odds ratio = 3.51; CI 95%: 2.83–4.37), and that the majority of infants included in their study were male (61%).

The current study also found that most operated cases were those of cleft lips (Table 1), indicating a higher prevalence of this type of cleft. This specific finding is different from those of the previous findings, where the prevalence of cleft lip and palate was higher than those of cleft lips or cleft palates alone.

In the current study, the difference in pain scores reduction between the control group and the experimental group was detected. This might be due to the effect of the curcumin patch applied in the experimental group. A study conducted by Anil et al on postsurgical patients that underwent a periodontal surgery procedure that evaluated the efficacy of curcumin as an inflammation and analgesic agent through the transmucosal route revealed that postoperative pain scores were significantly reduced in the experimental group. The transmucosal route of drug delivery ensures that the potential therapeutic agent has a maximum contact period of the desired concentration while also ensuring better drug absorption.

Another study conducted by Kriplani et al about the efficacy of curcumin-containing patches for the treatment of osteoarthritis also indicated the efficacy of curcumin in providing anti-inflammatory as well as analgesic effects for inflammation of the bone.

Additionally, previous evaluations of the effective curcumin dose in humans have been reported. In these human studies, curcumin was reported to be taken as much as 600 mg per day. Studies have reported 500 to 8,000 mg per day for short-term usage and 440 to 2,200 mg per day for long-term usage, and 180 mg per day for consumption period of 6 months. In our study, the dose of the curcumin patch was only 100 mg and was found to be significantly effective in reducing pain scores at 8 hours postsurgery. The low yet effective dose of curcumin might be due to the delivery method. Curcumin has been identified for its poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination. Delivery of curcumin through a transdermal route, a similar route to the one used in our study, has been known as a better delivery route to increase curcumin’s penetration efficacy. It was found that the release of curcumin through this delivery method will increase with time, which might be the underlying explanation for the significant difference in pain scores found on the eighth hour postsurgery.

The significant reduction in pain scores in the experimental group compared with the control group might be due to curcumin’s pathway as an analgesic agent. A preclinical study of curcumin showed its efficacy of curcumin in managing acute pain. Curcumin was proven to show antihyperalgesic activity by reversing mechanical hyperalgesia through a dose-dependent manner. Furthermore, when given in a repeated manner, curcumin was also proven to be effective in managing postoperative pain. Additionally, postoperative pain has been associated with an increased level of prostaglandin-E2 (PGE2) that is associated with postoperative inflammation. Inflammation, which is a natural process following surgery, will induce the release of several inflammation mediators that will then be followed by the infiltration of the inflammatory cells to the damaged site and the activation of nociceptive nerve fibers to produce pain signal. One of the mediators that are increased during the inflammation period of the postoperative healing period is PGE2, a mediator that was also found to be increased in patients with postoperative pain.

This increased level of PGE2 in postoperative patients is of advantage for curcumin’s mechanism of action as curcumin is known for its effect in downregulating PGE2. Additionally, previous evaluations of the effective curcumin dose in humans have been reported. In these human studies, curcumin was reported to be taken as much as 600 mg per day. Studies have reported 500 to 8,000 mg per day for short-term usage and 440 to 2,200 mg per day for long-term usage, and 180 mg per day for consumption period of 6 months. In our study, the dose of the curcumin patch was only 100 mg and was found to be significantly effective in reducing pain scores at 8 hours postsurgery. The low yet effective dose of curcumin might be due to the delivery method. Curcumin has been identified for its poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination. Delivery of curcumin through a transdermal route, a similar route to the one used in our study, has been known as a better delivery route to increase curcumin’s penetration efficacy. It was found that the release of curcumin through this delivery method will increase with time, which might be the underlying explanation for the significant difference in pain scores found on the eighth hour postsurgery.

The significant reduction in pain scores in the experimental group compared with the control group might be due to curcumin’s pathway as an analgesic agent. A preclinical study of curcumin showed its efficacy of curcumin in managing acute pain. Curcumin was proven to show antihyperalgesic activity by reversing mechanical hyperalgesia through a dose-dependent manner. Furthermore, when given in a repeated manner, curcumin was also proven to be effective in managing postoperative pain. Additionally, postoperative pain has been associated with an increased level of prostaglandin-E2 (PGE2) that is associated with postoperative inflammation. Inflammation, which is a natural process following surgery, will induce the release of several inflammation mediators that will then be followed by the infiltration of the inflammatory cells to the damaged site and the activation of nociceptive nerve fibers to produce pain signal. One of the mediators that are increased during the inflammation period of the postoperative healing period is PGE2, a mediator that was also found to be increased in patients with postoperative pain.

This increased level of PGE2 in postoperative patients is of advantage for curcumin’s mechanism of action as curcumin is known for its effect in downregulating PGE2. Additionally, previous evaluations of the effective curcumin dose in humans have been reported. In these human studies, curcumin was reported to be taken as much as 600 mg per day. Studies have reported 500 to 8,000 mg per day for short-term usage and 440 to 2,200 mg per day for long-term usage, and 180 mg per day for consumption period of 6 months. In our study, the dose of the curcumin patch was only 100 mg and was found to be significantly effective in reducing pain scores at 8 hours postsurgery. The low yet effective dose of curcumin might be due to the delivery method. Curcumin has been identified for its poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination. Delivery of curcumin through a transdermal route, a similar route to the one used in our study, has been known as a better delivery route to increase curcumin’s penetration efficacy. It was found that the release of curcumin through this delivery method will increase with time, which might be the underlying explanation for the significant difference in pain scores found on the eighth hour postsurgery.

The significant reduction in pain scores in the experimental group compared with the control group might be due to curcumin’s pathway as an analgesic agent. A preclinical study of curcumin showed its efficacy of curcumin in managing acute pain. Curcumin was proven to show antihyperalgesic activity by reversing mechanical hyperalgesia through a dose-dependent manner. Furthermore, when given in a repeated manner, curcumin was also proven to be effective in managing postoperative pain. Additionally, postoperative pain has been associated with an increased level of prostaglandin-E2 (PGE2) that is associated with postoperative inflammation. Inflammation, which is a natural process following surgery, will induce the release of several inflammation mediators that will then be followed by the infiltration of the inflammatory cells to the damaged site and the activation of nociceptive nerve fibers to produce pain signal. One of the mediators that are increased during the inflammation period of the postoperative healing period is PGE2, a mediator that was also found to be increased in patients with postoperative pain.

In summary, the current study showed a very promising future for curcumin to be used as an adjuvant analgesic agent for the management of acute orofacial pain due to operative procedures. And considering that our study applied a pragmatic design by following the standardized treatment protocol for acute pain management in postsurgery cleft lip and cleft palate patients, it can be concluded that the external validity of this study is high and therefore, the result is very much applicable in daily practice. Last but not least, considering the direct effect of curcumin on PGE2 found in...
preclinical studies, it is important to provide further evidence in future clinical studies.

Funding
The current research was funded by the Ministry of Research and Higher Education research grant (number: 1207/UN6.3.1/PT.00/2020).

Conflict of Interest
None declared.

Acknowledgment
The authors of the current study would like to acknowledge the doctors and nurses of the inpatient ward of Unpad Dental Hospital and the staff of the cleft lip and cleft palate foundation in Bandung, Indonesia, for their kind assistance and help during the research period.

References
35 Attiq A, Jalil J, Husain K, Ahmad W. Raging the war against inflammation with natural products. Front Pharmacol 2018;9:976